• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $GANX

    Gain Therapeutics Inc.

    Subscribe to $GANX
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics, Inc., a development stage biotechnology company, develops various therapeutics to treat diseases caused by protein misfolding. It focuses on lysosomal storage disorders, such as rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding treating the underlying disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: gaintherapeutics.com

    Recent Analyst Ratings for Gain Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    3/7/2025$12.00Sector Outperform
    Scotiabank
    12/6/2024$7.00Buy
    ROTH MKM
    8/14/2024$8.00Outperform
    Oppenheimer
    11/3/2021$21.00Buy
    B. Riley Securities
    See more ratings

    Gain Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Islam Khalid

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      6/25/25 5:30:23 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Richman Eric I

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      6/25/25 5:30:19 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Nicaise Claude

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      6/25/25 5:30:22 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hasler Hans Peter

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      6/25/25 5:30:17 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Riley Jeffrey Scott

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      6/25/25 5:30:20 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Goldstein Dov A Md

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      6/25/25 5:30:14 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Melincoff Gwen A

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      6/25/25 5:30:13 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by See Remark Fuggetta Gianluca

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      3/21/25 8:00:09 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO, President Mack Gene

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      3/21/25 8:00:04 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO, President Mack Gene

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      1/7/25 9:00:08 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Gain Therapeutics Inc. SEC Filings

    See more

    Gain Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    Gain Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more

    Gain Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Gain Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Gain Therapeutics, Inc. (0001819411) (Filer)

      6/30/25 4:30:29 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Gain Therapeutics, Inc. (0001819411) (Filer)

      6/24/25 5:09:42 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Gain Therapeutics Inc.

      S-3 - Gain Therapeutics, Inc. (0001819411) (Filer)

      5/28/25 5:01:17 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Gain Therapeutics Inc.

      10-Q - Gain Therapeutics, Inc. (0001819411) (Filer)

      5/14/25 4:08:52 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Gain Therapeutics, Inc. (0001819411) (Filer)

      5/14/25 4:06:21 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Gain Therapeutics Inc.

      DEFA14A - Gain Therapeutics, Inc. (0001819411) (Filer)

      4/29/25 4:07:47 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Gain Therapeutics Inc.

      DEF 14A - Gain Therapeutics, Inc. (0001819411) (Filer)

      4/29/25 4:05:41 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Gain Therapeutics Inc.

      PRE 14A - Gain Therapeutics, Inc. (0001819411) (Filer)

      4/17/25 4:05:19 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Gain Therapeutics, Inc. (0001819411) (Filer)

      4/10/25 4:49:46 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Gain Therapeutics Inc.

      10-K - Gain Therapeutics, Inc. (0001819411) (Filer)

      3/27/25 4:21:53 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Interim CEO Mack Gene bought $14,544 worth of shares (14,400 units at $1.01) (SEC Form 4)

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      8/12/24 5:23:31 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Chairman Islam Khalid bought $49,940 worth of shares (50,000 units at $1.00) (SEC Form 4)

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      8/12/24 5:23:30 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Richman Eric I bought $20,670 worth of shares (17,000 units at $1.22), increasing direct ownership by 6% to 289,629 units (SEC Form 4)

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      7/1/24 5:00:27 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Riley Jeffrey Scott bought $115,770 worth of shares (30,000 units at $3.86) (SEC Form 4)

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      4/1/24 4:01:37 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

      As of June 30th, 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025 Analysis of 90-day biomarker activity from cerebrospinal fluid (CSF) in all participants currently enrolled is now expected to also track earlier; available in 4Q 2025 instead of 1Q 2026 Gain will continue screening patients for enrollment through July 31st, 2025, at the request of clinical investigators and additional participants who wish to gain access to the study The independent data monitoring committee (DMC) met recently and recommended to continue the study with no changes in dose level; no serious treatment emergent adverse events (TEAEs) h

      6/30/25 4:05:00 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics to Participate in Upcoming Investor Conferences

      BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference Tuesday, June 17, at 7:00 a.m. EST: Gene Mack will participate in a virtual fireside chat with Raghuram Selvaraju, Ph.D. BIO 2025 Wednesday, June 18, at 1:45 p.m. EST: Gene Mack will give a corporate presentation in Room 153C at the Boston Convention and Exhibition

      6/10/25 8:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

      BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the GBA1 Meeting 2025, being held June 5th-7th in Montreal, Canada. Details of the oral presentation are as follows: Date: Thursday, June 5, 2025 Time: 11:20 p.m. EST Presenter: Jonas Hannestad, M.D., Ph.D., Chief Medical Officer, Gain Therapeutics About Gain Therapeutics, Inc.Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generatio

      5/29/25 8:45:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

      BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. "The first quarter of 2025 marked yet another exciting milestone for Gain with the first administration of GT-02287, our lead drug candidate in development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation, to participants with Parkinson's disease in our ongoing Phase 1b study which began enrollment in early M

      5/14/25 7:30:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

      BETHESDA, Md., May 12, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a guided poster presentation was made at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease and Related Disorders, held May 7th-10th in New York City, NY. The poster outlined new evidence supporting GT-02287's ability to provide a broader neuroprotective effect and potential as a disease-modifying therapy for Parkinson's disease. "We have continued to

      5/12/25 7:30:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics to Participate at The Citizens Life Sciences Conference

      BETHESDA, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present and participate in one-on-one meetings at The Citizens Life Sciences Conference, being held May 7th-8th in New York City, NY. Details of the presentation are as follows: Date: Thursday, May 8, 2025 Time: 12:00 p.m. EST Please contact your representative at Citizens if you would like to set up a one-on-one meeting with management. An archived replay of the presentat

      5/1/25 7:30:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

      BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral poster presentation at the International Association of Parkinsonism and Related Disorders (IAPRD) 30th World Congress on Parkinson's Disease and Related Disorders, being held May 7th-10th in New York City, NY. Details of the oral and poster presentation are as follows: Presentation Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson's Disease, Protects Dopaminergic Neu

      4/30/25 7:45:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

      GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson's disease models Enrollment update provided for Phase 1b study Phase 1b study ongoing to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of GT-02287 in people with Parkinson's disease; biomarker analysis to be conducted in Q2 2025 BETHESDA, Md., April 10, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that an oral presentation as well as a poster were pres

      4/10/25 7:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Announces Poster Presentation at AD/PD 2025

      BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the design of the Phase 1b clinical trial of GT-02287 in Parkinson's disease will be presented at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders. AD/PD™ 2025 is being held April 1-5, 2025, in Vienna, Austria. Details of the poster are as follows: Poster Number: SHIFT 02-072 Poster Title: Design of a Phase 1b Study to

      3/28/25 8:30:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

      BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update. "2024 was a year of significant progress for Gain, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without GBA1 mutation," said Gene Mack, President and CEO

      3/27/25 7:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Gain Therapeutics with a new price target

      Scotiabank initiated coverage of Gain Therapeutics with a rating of Sector Outperform and set a new price target of $12.00

      3/7/25 8:20:06 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Gain Therapeutics with a new price target

      ROTH MKM initiated coverage of Gain Therapeutics with a rating of Buy and set a new price target of $7.00

      12/6/24 7:48:38 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Gain Therapeutics with a new price target

      Oppenheimer resumed coverage of Gain Therapeutics with a rating of Outperform and set a new price target of $8.00

      8/14/24 7:36:01 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Gain Therapeutics with a new price target

      B. Riley Securities initiated coverage of Gain Therapeutics with a rating of Buy and set a new price target of $21.00

      11/3/21 4:59:34 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Gain Therapeutics with a new price target

      Oppenheimer initiated coverage of Gain Therapeutics with a rating of Outperform and set a new price target of $14.00

      4/12/21 7:20:49 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Gain Therapeutics with a new price target

      BTIG Research initiated coverage of Gain Therapeutics with a rating of Buy and set a new price target of $30.00

      4/12/21 6:40:49 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Gain Therapeutics with a new price target

      Oppenheimer initiated coverage of Gain Therapeutics with a rating of Outperform and set a new price target of $30.00

      4/12/21 6:40:18 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Gain Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

      Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024 Gianluca Fuggetta Will Assume The Role Of Senior Vice President, Finance BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, who has served as the Company's Chief Financial Officer since April 2024 and interim Chief Executive Officer since June 2024, has been appointed President and Chief Executive Officer, effective January 6, 2025. Mr. Mack has also been appointed as a me

      1/7/25 7:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

      Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities. Upon Mr. Alder's departure, the Company appointed Gene Mack, the Company's current Chief Financial Officer, as interim Chief Executive Officer, effective June 25, 2024. Mr. Mack will retain his role as Chief Finan

      6/27/24 4:08:08 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

      BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024. "We are thrilled to welcome Gene as our new CFO," commented Gain CEO Matthias Alder. "His experience as an operational CFO with a track record of successful financing, M&A and other strategic transactions combined with his scientific background and career as an equity research analyst ideally complement our executive man

      4/8/24 9:25:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

      BETHESDA, Md., April 01, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation allosteric small molecule therapies, today announces the appointment of Jonas Hannestad, M.D., Ph.D. as its chief medical officer, effective as of March 25, 2024. "I am pleased to welcome Jonas to Gain and look forward to his contributions. His extensive development experience and in-depth scientific background in Parkinson's and other neurodegenerative diseases will be invaluable as we advance our GT-02287 program through the ongoing Phase 1 clinical trial into further

      4/1/24 9:25:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics' CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update

      BETHESDA, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain," or the "Company"), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today releases the following letter to stockholders from its President and Chief Executive Officer Matthias Alder. Dear Fellow Stockholders, With the start of a new year, I want to take a moment to reflect on Gain's progress over the last 12 months and to share our strategy and plans for 2024. Research and development of pharmaceutical products for the treatment of neurodegenerative diseases has seen tremendous progress in recent years, with the approval of new drugs for th

      1/31/24 8:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer

      BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballantyne as the Company's Chief Financial Officer, effective immediately. Mr. Ballantyne succeeds Salvatore Calabrese, who is expected to remain employed by the Company for a reasonable transition period to enable an orderly transition of duties. "I am thrilled to be joining the Gain team at this exciting time in the Company's development," said Mr. Ballantyne, Chief Financial Officer. "Gain's lead program with disease-modifyi

      4/12/23 4:30:00 PM ET
      $AGEN
      $GANX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Gain Therapeutics, Inc. Announces Appointment of Five Members to its Newly Formed Scientific Advisory Board (SAB)

      BETHESDA, Md., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "company"), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced the formation of its Scientific Advisory Board (SAB). Luca Benatti, Ph.D. will serve as chair of the SAB. Additional appointments include Samuel Broder, M.D.; Lorenzo Leoni, Ph.D.; Joanne Taylor, Ph.D.; and Michel Vellard, Ph.D. "I am honored to welcome Dr. Benatti, Dr. Broder, Dr. Leoni, Dr. Taylor and Dr. Vellard to our advisory board and want to express my gratitude for their scientific c

      10/26/21 8:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer

      BETHESDA, Md., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced the appointment of Matthias Alder as Chief Operating Officer to advance the Company's strategic and operational objectives, including the establishment of additional industry partnerships and the transition of the Company's lead program in Gaucher and Parkinson's Disease into clinical trials, which is expected to occur in 2022. "I am delighted to welcome Matthias to Gain's growing team as we

      10/19/21 8:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coya Therapeutics™ Announces the Appointment of Hideki Garren, M.D., Ph.D., and Dov Goldstein, M.D., to Its Board of Directors

      HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya™), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced that it has appointed Hideki Garren, M.D., Ph.D., Chief Medical Officer of Prothena and Dov Goldstein, M.D., Chief Financial Officer and Chief Business Officer of Indapta, to the Company's Board of Directors, effective immediately. Coya's Board is now composed of five members. "We are pleased to welcome these world-class leaders to our board; their expertise in research and development of

      4/14/21 7:00:00 AM ET
      $NBSE
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Gain Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

      BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. "The first quarter of 2025 marked yet another exciting milestone for Gain with the first administration of GT-02287, our lead drug candidate in development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation, to participants with Parkinson's disease in our ongoing Phase 1b study which began enrollment in early M

      5/14/25 7:30:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

      BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update. "2024 was a year of significant progress for Gain, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without GBA1 mutation," said Gene Mack, President and CEO

      3/27/25 7:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

      BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended September 30, 2024, and provides a corporate update. "The third quarter of 2024 marked substantial progress for Gain and the development of GT-02287, our lead candidate for the treatment of Parkinson's disease in patients with or without the GBA1 mutation. Data from our Phase 1 study for GT-02287 presented recently at both the International Congress of Parkinson's Disease and Movement

      11/14/24 4:05:00 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

      Company To Discuss Positive Results Presented at the International MDS Congress and the Design of Phase 1b Trial in Parkinson's Disease Patients Event Will Be Held on Monday, September 30, 2024, at 8:30 am ET BETHESDA, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it is holding a webinar to discuss data from the Phase 1 study of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson's disease, recently presented in a late-breaker at the International Congress

      9/26/24 7:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

      BETHESDA, Md., June 28, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that interim-CEO and current CFO Gene Mack will host a business and corporate update call on Monday, July 1, 2024, beginning 8:30am ET pre-market open. Participants can join the conference call through the News and Events section of the Company website at https://www.gaintherapeutics.com/investors-media/news-events. A recorded version and transcript of the call will be archived and available for replay in the News and Even

      6/28/24 4:39:04 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

      BETHESDA, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended March 31, 2024, and provides a corporate update. Corporate Highlights from Q1 2024 to Date Announced Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287Strengthened management team with appointment of Gene Mack as Chief Financial Officer and Jonas Hannestad, M.D., Ph.D. as Chief Medical OfficerPresented data at AD/PD 2024 demonstrating m

      5/14/24 7:30:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

      Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson's Disease Therapeutic, GT-02287 Promoted Matthias Alder to Chief Executive Officer and Appointed him to the Board of Directors $25.7 Million in Cash and Cash Equivalents and Marketable Securities as of September 30, 2022 Provides Strong Financial Foundation and Extends Cash Runway into Q2 2024 BETHESDA, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allos

      11/10/22 4:02:00 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update

      BETHESDA, Md., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced its financial results for the second quarter ended June 30, 2022, and highlighted recent corporate progress. "We move into the second half of 2022 having made tangible progress across our pipeline," said Eric Richman, Chief Executive Officer of Gain Therapeutics. "We continued to expand the body of positive preclinical data on our lead programs in Parkinson's disease and Gau

      8/8/22 8:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update

      Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson's Disease and Gaucher's Disease. $34.34 Million in Cash as of March 31, 2022, Provides Runway into Second half of 2023 and a Strong Cash Position to Transition the Company's Lead Program into Clinical Trials BETHESDA, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced its

      5/16/22 4:05:00 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update

      $36.88 Million in cash as of December 31, 2021, provides runway into second half of 2023 and a strong cash position to transition the Company's lead program into clinical trials ---Compelling preclinical data presented on lead program GBA1 Parkinson's Disease at multiple scientific conferences supports transition to clinical stage company with FIH trial by year end --- Entered into multi-target deal with Zentalis Pharmaceuticals to identify novel small molecules for oncology indications  BETHESDA, Md., March 24, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a biotechnology company focused on identifying and optimizing allosteric binding sites t

      3/24/22 8:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Gain Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gain Therapeutics Inc.

      SC 13G/A - Gain Therapeutics, Inc. (0001819411) (Subject)

      3/29/21 11:59:04 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care